Literature DB >> 2961880

Comparison of serotonergic receptor subtypes on the smooth muscle and endothelium of the canine coronary artery.

D S Houston1, P M Vanhoutte.   

Abstract

To characterize the responses of the canine coronary artery to serotonin, rings with and without endothelium were suspended in organ chambers for isometric tension recording. Serotonin evoked an endothelium-dependent relaxation of prostaglandin F2 alpha-contracted rings which was inhibited by antagonists with affinity for 5-hydroxytryptamine (5-HT)1 and 5-HT2 receptors, methiothepin and metergoline, but was not mimicked or antagonized by the 5-HT1A-selective ligand, 8-hydroxy-2-di-n-propylamino tetralin. This relaxation is not mediated by 5-HT1B receptors as it was not antagonized by cyanopindolol; similarly, lack of inhibition by ketanserin and MDL 72222 rule out contributions of 5-HT2 receptors or 5-HT3 receptors. Rings without endothelium contracted to serotonin; this contraction was not blocked by cyanopindolol and was only weakly inhibited by ketanserin, but was antagonized in an apparently competitive fashion by methiothepin and was mimicked by 8-hydroxy-2-di-n-propylamino tetralin (although at higher concentrations than would be expected for its action at a 5-HT1A receptor). At high concentrations, serotonin evoked a relaxation of endothelium-denuded rings, which was blocked by very low concentrations of methiothepin but was unaffected by ketanserin or cyanopindolol. Thus, there appear to be three different serotonergic receptors in the coronary artery. Although available agents do not allow their precise classification as yet, none of them is of the 5-HT2 type.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2961880

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  16 in total

1.  Contractions to 5-hydroxytryptamine in human coronary artery and human saphenous vein.

Authors:  M Borton; M Neligan; F Wood; P Dervan; K Goggins; J R Docherty
Journal:  Br J Clin Pharmacol       Date:  1990       Impact factor: 4.335

2.  Characterization of an endothelial 5-hydroxytryptamine (5-HT) receptor mediating relaxation of the porcine coronary artery.

Authors:  G J Molderings; G Engel; E Roth; M Göthert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-09       Impact factor: 3.000

3.  Systemic vascular endothelial cell dysfunction in normal pressure glaucoma.

Authors:  Christine Buckley; Patrick W F Hadoke; Emer Henry; Colm O'Brien
Journal:  Br J Ophthalmol       Date:  2002-02       Impact factor: 4.638

Review 4.  Possible roles of 5-HT in vein graft failure due to intimal hyperplasia 5-HT, nitric oxide and vein graft.

Authors:  Akio Kodama; Takeo Itoh; Kimihiro Komori
Journal:  Surg Today       Date:  2013-03-28       Impact factor: 2.549

5.  Treatment with isoproterenol of bupivacaine toxicity.

Authors:  P Lacombe; G Blaise; F Plante; C Hollmann
Journal:  Can J Anaesth       Date:  1990-05       Impact factor: 5.063

6.  [3H]ketanserin binding in human brain postmortem.

Authors:  D Marazziti; A Rossi; L Palego; G Giannaccini; A Naccarato; A Lucacchini; G B Cassano
Journal:  Neurochem Res       Date:  1997-06       Impact factor: 3.996

7.  The relaxant 5-HT receptor in the dog coronary artery smooth muscle: pharmacological resemblance to the cloned 5-ht7 receptor subtype.

Authors:  J A Terrón
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

Review 8.  Cardiovascular responses produced by 5-hydroxytriptamine:a pharmacological update on the receptors/mechanisms involved and therapeutic implications.

Authors:  Carlos M Villalón; David Centurión
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-08-17       Impact factor: 3.000

Review 9.  Serotonergic antagonists and vascular disease.

Authors:  P M Vanhoutte
Journal:  Cardiovasc Drugs Ther       Date:  1990-01       Impact factor: 3.727

Review 10.  Endothelial vasomotor regulation in health and disease.

Authors:  N R Searle; P Sahab
Journal:  Can J Anaesth       Date:  1992-10       Impact factor: 5.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.